Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,635 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non Insulin Dependent Diabetes Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to GLP1R Agonists

NCT05071898
View directory record Official record
Conditions
Obesity, Diabetes Type 2
Interventions
Semaglutide Pen Injector [Ozempic]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

NCT02607865
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Type 2 Diabetes Self-management Intervention for Low-income Women

NCT01284465
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Education and patient liaison combination, Control group
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
21 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 17, 2026, 5:04 AM EDT
Active, not recruiting No phase listed Observational

Biological Sample Repository for Gastrointestinal Disorders

NCT05874726
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder, Overweight and Obesity, Overweight, Overweight or Obesity, Diabetes Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemias, Sleep Apnea, GERD, Gastroesophageal Reflux, Musculoskeletal Pain Disorder, Cancer
Interventions
Blood Collection, Urine Collection, Tissue Sample Collection
Diagnostic Test
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

NCT00909597
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
pioglitazone, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
57
States / cities
Buena Park, California • Chino, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

NCT01272232
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

NCT02585778
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encino, California • Fresno, California • Oakland, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 17, 2026, 5:04 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074
View directory record Official record
Conditions
CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of PJ vs. Sugar on Glucose Levels in Healthy and Prediabetic Subjects

NCT04591782
View directory record Official record
Conditions
Diabete Type 2, Pre Diabetes
Interventions
PomJuice, Water, Sugar Water
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 1 Interventional

A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

NCT00519480
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, Metformin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 17, 2026, 5:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
View directory record Official record
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

NCT00385697
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Teplizumab, Placebo
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
8 Years to 35 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
39
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Not applicable Interventional Results available

Closed Loop Glucose Control in Patients With Type 2 Diabetes

NCT05386849
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
FUSION closed loop glucose control system
Device
Lead sponsor
Ideal Medical Technologies
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

NCT03449199
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
TMX-049, Placebo
Drug
Lead sponsor
Teijin America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
55
States / cities
Flagstaff, Arizona • Mesa, Arizona • Alhambra, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

NCT06948747
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

NCT00823992
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Bermuda Dunes, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Not applicable Interventional

The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication

NCT04632849
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GEM + CGM
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
35 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 1 Interventional

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

NCT00952198
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ARRY-403, glucokinase activator; oral, Placebo; oral
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 4 Interventional Results available

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NCT04538352
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Semaglutide, Insulin Degludec, Insulin aspart
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 17, 2026, 5:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

NCT00222807
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Delusional Disorder
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Phase 4 Interventional

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

NCT03970044
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide 2 MG, Dapagliflozin 10 MG
Drug
Lead sponsor
Consano Clinical Research, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Shavano Park, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Sep 17, 2026, 5:04 AM EDT
Completed Not applicable Interventional

Multi-clinic Action Trial to Control Hyperglycemia and Hypertension

NCT02759484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Home Based Enhanced Education, Clinic Based Enhanced Education
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Cicero, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 17, 2026, 5:04 AM EDT
Withdrawn Early Phase 1 Interventional

Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus

NCT02444364
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Sitagliptin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 17, 2026, 5:04 AM EDT